Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CD36 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD36, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD34 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD34, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD33 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD33, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD28 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD28, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD27 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD27, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD24 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD24, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD22 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD22, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD14 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD14, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD8B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD8B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD8A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD8A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD7 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD7, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CD6 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
20 July 2026
A visual target evaluation report for CD6, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.